ENDV (Endonovo Therapeutics) Retained Earnings: $-72.12 Mil (As of Jun. 2025)


What is Endonovo Therapeutics Retained Earnings?

Endonovo Therapeutics ENDV Retained Earnings is $-72.12 Mil as of Jun. 2025.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Endonovo Therapeutics's retained earnings for the quarter that ended in Jun. 2025 was $-72.12 Mil.

Endonovo Therapeutics's quarterly retained earnings declined from Dec. 2024 ($-71.03 Mil) to Mar. 2025 ($-71.56 Mil) and declined from Mar. 2025 ($-71.56 Mil) to Jun. 2025 ($-72.12 Mil).

Endonovo Therapeutics's annual retained earnings increased from Dec. 2022 ($-75.12 Mil) to Dec. 2023 ($-68.23 Mil) but then declined from Dec. 2023 ($-68.23 Mil) to Dec. 2024 ($-71.03 Mil).

Endonovo Therapeutics  (OTCPK:ENDV) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Endonovo Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Endonovo Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Endonovo Therapeutics Retained Earnings Chart

Endonovo Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -53.34 -56.44 -75.12 -68.23 -71.03

Endonovo Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.67 -70.36 -71.03 -71.56 -72.12

Endonovo Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-72.12 Mil mean?
Endonovo Therapeutics (ENDV) has a Retained Earnings of $-72.12 Mil as of Jun. 2025. Retained earnings is the amount of net income not issued to shareholders. View historical data on Endonovo Therapeutics and its competitors.
Is Endonovo Therapeutics' Retained Earnings too high?
Endonovo Therapeutics' current Retained Earnings is $-72.12 Mil.
How does Endonovo Therapeutics' Retained Earnings compare to RGBP and SIGY?
Endonovo Therapeutics' Retained Earnings of $-72.12 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Endonovo Therapeutics and its competitors. Endonovo Therapeutics's current Retained Earnings is $-72.12 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Endonovo Therapeutics stock overvalued right now?
Endonovo Therapeutics (ENDV) has a current Retained Earnings of $-72.12 Mil. The current Retained Earnings is $-72.12 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Endonovo Therapeutics (ENDV), the current Retained Earnings is $-72.12 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Endonovo Therapeutics Business Description

Address 6320 Canoga Avenue, 15th Floor, Woodland Hills, CA, USA, 91367
Endonovo Therapeutics Inc develops, manufactures and distributes revolutionary medical devices that utilize Pulsed Electro Magnetic Field (PEMF) therapy that are focused on the rapid recovery of wounds and reduction of pain, edema and inflammation on and in the human body.